XTL Biopharmaceuticals (NASDAQ:XTLB) vs. Neuphoria Therapeutics (NASDAQ:NEUP) Financial Comparison

Neuphoria Therapeutics (NASDAQ:NEUP) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitability.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Neuphoria Therapeutics and XTL Biopharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1	2	0	0	1.67
XTL Biopharmaceuticals	1	0	0	0	1.00

Neuphoria Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 89.19%. Given Neuphoria Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Neuphoria Therapeutics is more favorable than XTL Biopharmaceuticals.

Valuation & Earnings

This table compares Neuphoria Therapeutics and XTL Biopharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65 million	1.28	-$370,000.00	($11.06)	-0.33
XTL Biopharmaceuticals	$450,000.00	11.96	-$6.97 million	($0.64)	-3.55

Neuphoria Therapeutics has higher revenue and earnings than XTL Biopharmaceuticals. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Neuphoria Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

Profitability

This table compares Neuphoria Therapeutics and XTL Biopharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
XTL Biopharmaceuticals	N/A	N/A	N/A

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.